$0.14
+0.00 (+2.21%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GOSS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 4 with posted results
Held by 12 tracked-famous managers (D. E. Shaw & Co., Inc., AQR CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, Qube Research & Technologies Ltd, +7 more) · FINRA short interest 1.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| GB5121 in Adult Patients With Relapsed/Refractory CNS LymphomaNCT05242146Phase 1b Dose Escalation - Incidence of Adverse EventsOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: GB5121 | CNS Lymphoma | 12 | 2023-05-11actual | 2023-06-13 |
| GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)NCT04456998results2023-11-07Change From Baseline to Week 24 in Pulmonary Vascular Resistance (PVR)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: GB002 (seralutinib), Placebo · Device: Generic Dry Powder Inhaler | Pulmonary Artery Hypertension | 86 | 2022-10-17actual | 2023-11-07 |
| GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaNCT04060342Phase 1 Dose Escalation - Regimens A, B,and C: Incidence of dose limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Drug: GB1275, nab-paclitaxel and gemcitabine, pembrolizumab | Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma | 61 | 2022-04-11actual | 2022-08-18 |
| Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial HypertensionNCT03926793Number of participants with Treatment-Related Adverse Events GB002 (Main study)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: GB002, Placebo · Device: Generic Dry Powder Inhaler | Pulmonary Arterial Hypertension | 8 | 2021-05-05actual | 2021-09-01 |
| GB001 in Adult Subjects With Moderate to Severe AsthmaNCT03683576results2021-08-23Proportion of Participants Who Experience Worsening of Asthma by Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: GB001, Placebo | Asthma | 481 | 2020-07-23actual | 2021-09-16 |
| GB001 in Adult Participants With Chronic RhinosinusitisNCT03956862results2021-07-30Change From Baseline to Week 16 in Sino-Nasal Outcome Test (SNOT) 22 Total ScoreRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: GB001, Placebo | Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 97 | 2020-07-09actual | 2021-08-23 |
| GB004 in Adult Subjects With Active Ulcerative ColitisNCT03860896Incidence of treatment emergent adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: GB004, Placebo, GB004 | Ulcerative Colitis | 34 | 2019-12-17actual | 2020-01-14 |
| Phase 1A Safety Trial of Inhaled PK10571 (GB002)NCT03473236results2020-02-17Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: GB002, Placebo · Device: Generic Dry Powder Inhaler | Safety Issues | 66 | 2018-12-03actual | 2020-06-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19